Interleukin-23 Antagonist [EPC]

126723 reported adverse events

Drugs of this class: GUSELKUMAB RISANKIZUMAB-RZAA TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 14456
1 PSORIASIS 11834
2 PRODUCT DOSE OMISSION ISSUE 10438
3 OFF LABEL USE 9987
4 FATIGUE 5791
5 PAIN 5433
6 ARTHRALGIA 5155
7 HEADACHE 4721
8 PRODUCT USE ISSUE 4663
9 RASH 4315
See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SWOLLEN JOINT COUNT INCREASED 691 0.6600
1 LUPUS VULGARIS 107 0.6185
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 125 0.5814
3 RHEUMATIC FEVER 824 0.5750
4 DEEP VEIN THROMBOSIS POSTOPERATIVE 247 0.5563
5 RED BLOOD CELL SEDIMENTATION RATE 127 0.4903
6 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1820 0.4743
7 RHEUMATOID FACTOR POSITIVE 1574 0.4531
8 C-REACTIVE PROTEIN 97 0.3834
9 DUODENAL ULCER PERFORATION 1153 0.3306
See all enriched reactions for Interleukin-23 Antagonist [EPC]